FDA Will Review Its Mifepristone Prescribing, Dispensing Requirements

HHS Secretary Xavier Becerra on Friday (May 7) told a Hawaii district court that FDA will review and consider potential modifications to its in-person prescribing and dispensing restrictions on abortion drug mifepristone, coming less than a month after the agency announced it had temporarily lifted the restrictions for the duration of the public health emergency. FDA is expected to provide an update on its review by Nov. 1. In the meantime, at the request of Becerra and the American Civil...